Yuko Oya

Scopus著者プロファイル

h-index

年別の研究成果

フィンガープリント

Yuko Oyaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。

1 類似のプロファイル

47 学術論文
9 総説
1 コメント/討論

How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancy
Ninomiya, K., Miura, S., Oya, Y., Sakamoto, T., Tanaka, K., Teraoka, S., Morise, M. & Morita, S., 2025, (印刷中) In: International Journal of Clinical Oncology. c117.
研究成果: ジャーナルへの寄稿 › 学術論文 › 査読
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study
Okada, A., Sakata, Y., Oya, Y., Sakata, S., Yamaguchi, T., Tamiya, M., Suzuki, H., Shibaki, R., Yokoyama, T., Matsumoto, H., Otsuki, T., Sato, Y., Uchida, J., Saito, G., Tsukita, Y., Inaba, M., Ikeda, H., Arai, D., Maruyama, H. & Hara, S. & 2 others, Tsumura, S. & Sakagami, T., 06-2025, In: Lung Cancer. 204, 108589.
研究成果: ジャーナルへの寄稿 › 学術論文 › 査読
Latest Advances in Perioperative care for Resectable Non-small lung cancer
Oya, Y. & Tanaka, I., 07-2025, In: Respiratory Investigation. 63, 4, p. 532-541 10 p.
研究成果: ジャーナルへの寄稿 › 総説 › 査読

Open Access
Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))
Sakata, Y., Saito, G., Sakata, S., Oya, Y., Tamiya, M., Suzuki, H., Shibaki, R., Okada, A., Yokoyama, T., Matsumoto, H., Otsuki, T., Sato, Y., Junji, U., Tsukita, Y., Inaba, M., Ikeda, H., Arai, D., Maruyama, H., Hara, S. & Tsumura, S. & 2 others, Morinaga, J. & Sakagami, T., 02-2024, In: Lung Cancer. 188, 107450.
研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読
It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
Akao, K., Oya, Y., Sato, T., Ikeda, A., Horiguchi, T., Goto, Y., Hashimoto, N., Kondo, M. & Imaizumi, K., 2024, In: Exploration of Targeted Anti-tumor Therapy. 5, 4, p. 826-840 15 p.
研究成果: ジャーナルへの寄稿 › 総説 › 査読

Open Access
1 被引用数 (Scopus)

大矢由子

研究者プロファイル

フィンガープリント

過去5年の共同研究と上位研究分野

詳細を開く

How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancy

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study

Latest Advances in Perioperative care for Resectable Non-small lung cancer

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

大矢 由子

研究者プロファイル

フィンガープリント

過去5年の共同研究と上位研究分野

研究成果

How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancy

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study

Latest Advances in Perioperative care for Resectable Non-small lung cancer

Corrigendum to “Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)” [Lung Cancer 186 (2023) 107426] (Lung Cancer (2023) 186, (S0169500223009649), (10.1016/j.lungcan.2023.107426))

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

大矢由子